XML 68 R51.htm IDEA: XBRL DOCUMENT v3.21.2
Balance Sheet Components - Additional Information (Detail) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2021
Dec. 31, 2020
Schedule of Available-for-sale Securities [Line Items]      
Cash and cash equivalents $ 353,361,000 $ 353,361,000 $ 678,393,000
Other-than-temporary impairment loss $ 0 $ 0  
Percentage of pre-launch inventory capitalized of aggregate inventory balance 37.00% 37.00% 29.00%
Net unbilled co-development revenue $ 0 $ 0 $ 0
Profit share liability 25,234,000 25,234,000 6,547,000
AstraZeneca Agreements [Member]      
Schedule of Available-for-sale Securities [Line Items]      
Net unbilled co-development revenue 5,300,000 5,300,000  
AstraZeneca Agreements [Member] | China [Member]      
Schedule of Available-for-sale Securities [Line Items]      
Profit share liability 7,000,000.0 $ 7,000,000.0 7,000,000.0
Maximum [Member]      
Schedule of Available-for-sale Securities [Line Items]      
Contractual maturities of available-for-sale investments   2 years  
Foreign subsidiaries [Member]      
Schedule of Available-for-sale Securities [Line Items]      
Cash and cash equivalents $ 85,100,000 $ 85,100,000 $ 66,000,000.0